Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Tariquidar and Docetaxel in Treating Patients With Recurrent or Metastatic Lung, Ovarian, Cervical Cancer, or Kidney Cancer
This study is ongoing, but not recruiting participants.
Study NCT00072202 Information provided by National Cancer Institute (NCI)
First Received: November 4, 2003 Last Updated: April 9, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cervical Cancer
Fallopian Tube Cancer
Kidney Cancer
Lung Cancer
Ovarian Cancer
Peritoneal Cavity Cancer
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Fallopian Tube Neoplasms
Kidney Neoplasms
Lung Neoplasms
Ovarian Neoplasms
Peritoneal Neoplasms
More general conditions related to this trial
Abdominal Neoplasms
Adenocarcinoma
Adnexal Diseases
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Kidney Diseases
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Ovarian Diseases
Peritoneal Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
docetaxel
tariquidar
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
